TY  - JOUR
AU  - Sprave, Tanja
AU  - Verma, Vivek
AU  - Sterzing, Florian
AU  - Bruckner, Thomas
AU  - Hees, Katharina
AU  - Land, Beate
AU  - Jäkel, Oliver
AU  - Herfarth, Klaus
AU  - Debus, Jürgen
AU  - Uhl, Matthias
TI  - Cost-Effectiveness of Carbon Ion Radiation Therapy for Skull Base Chordoma Utilizing Long-Term (10-Year) Outcome Data.
JO  - Anticancer research
VL  - 38
IS  - 8
SN  - 1791-7530
CY  - Attiki
M1  - DKFZ-2018-01919
SP  - 4853 - 4858
PY  - 2018
AB  - Carbon ion radiotherapy (CIRT) offers high conformality and ability to dose-escalate skull base chordomas, with promising clinical data. However, it is an imperative measure to economically justify the use of such high-priced new technologies. Herein, we investigated the cost-effectiveness of CIRT compared to photon radiotherapy (PRT) using 10-year outcome data extrapolated to a 34-year time frame.Data regarding costs of PRT, as well as 10-year outcomes were obtained from published sources. Corresponding figures for CIRT were acquired from institutional and published sources. Adjustment was made in order to compare both cost figures, including elimination of additional financing and follow-up, so that only direct costs of treatment and the cost of progression were compared between both modalities. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in cost between both modalities divided by the difference in 34-year quality-adjusted life-year (QALY) outcomes. The annual gross domestic product per capita cost-effectiveness threshold definition (as recommended by the WHO) was employed.The total cost of a complete course of CIRT (20-22 fractions) was €31,538.21. After removal of financing and follow-up costs, the adjusted direct cost of CIRT utilized for comparison was €18,957.78. In a previous publication, the cost of PRT was €4,700.00. ICERs were based upon these direct cost figures and the average of reported 10-year progression-free survival (PFS) values with PRT (41.1
KW  - Antineoplastic Agents (NLM Chemicals)
KW  - Imatinib Mesylate (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:30061259
DO  - DOI:10.21873/anticanres.12797
UR  - https://inrepo02.dkfz.de/record/141413
ER  -